SUNPHARMA

's Resilience: A Shift from Generics to Specialty Drugs

's shares remained stable despite the US FDA's "Official Action Indicated" (OAI) classification on its Halol plant. This resilience, despite export restrictions on multiple facilities, is due to the company's strategic shift away from its traditional US generics business. → Declining Reliance on US Generics: The company's financial performance remains strong because it has reduced its dependence on the US generic drug market. Over the past few years, Sun Pharma's US generics revenue (excluding specialty drugs) has seen a decline, impacted by facility issues and price erosion. Due to lower profit margins, the generic drug business contributes less to Sun Pharma's overall operating earnings compared to its peers. → Focus on High-Growth Segments: Sun Pharma's new strategic focus is on high-margin patented specialty drugs, a significant portion of which are manufactured by contract partners outside of India, making them immune to the FDA's export restrictions on domestic plants. The India business is another key growth driver, consistently outperforming the domestic market. Although it accounts for only a third of the company's total sales, it contributes approximately 55% of the overall EBITDA. → Risks and Future Outlook: While Sun Pharma's diversified revenue base has helped it navigate regulatory hurdles, the company remains vulnerable to potential policy changes in the US, such as price restrictions on specialty drugs. Investors should monitor these policy developments, as they could have a significant impact on the company's future revenue and profitability.